Sugi Predict

Sugi Predict / Compounds / SCHEMBL614030

SCHEMBL614030

SCHEMBL614030

Cc1cc(=O)oc2cc(NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@]3(CC(C)C)NC(=O)CCC3=O)C(C)C)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.36
▸ CA12 O43570 2/20 0.35
▸ CA1 P00915 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ KDM4E B2RXH2 9/20 0.35
▸ ALDH1A1 P00352 9/20 0.35
▸ HPGD P15428 7/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ GAA P10253 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2359561 0.92 TDP1 (0.42) TDP1CA12CA1CA9KDM4E
SCHEMBL5675554 0.83 TDP1 (0.42) TDP1CA12CA1CA9KDM4E
SCHEMBL29419658 0.83 TDP1 (0.42) TDP1CA12CA1CA9KDM4E
SCHEMBL1193133 0.82 TDP1 (0.39) TDP1CA12CA1CA9KDM4E
SCHEMBL29364275 0.82 KDM4E (0.53) TDP1CA12CA1CA9KDM4E
SCHEMBL4755762 0.82 KDM4E (0.53) TDP1CA12CA1CA9KDM4E
SCHEMBL29543547 0.81 TDP1 (0.44) TDP1CA12CA1CA9KDM4E
SCHEMBL15571611 0.81 TDP1 (0.44) TDP1CA12CA1CA9KDM4E
SCHEMBL14968851 0.78 KDR (0.39) —
SCHEMBL30887566 0.77 CA12 (0.48) TDP1CA12CA1CA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106995490-A A kind of method of regulation and control plant rennet body activity 中国科学院上海生命科学研究院 2017-08-01 — — CN disclosed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 — — EP disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 — — US disclosed
WO-2014161072-A1 Α-BORYL ISOCYANIDES, BOROPEPTIDES AND BORON HETEROCYCLES THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2014-10-09 — — WO disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 — — US disclosed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 — — US disclosed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 — — US disclosed
CN-102641223-A Cosmetic composition for improving skin tone or skin elasticity AMOREPACIFIC CORP 2012-08-22 — — CN disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 — — US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 — — US disclosed
US-20050059636-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. 2005-03-17 — — US disclosed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 — — WO disclosed
WO-2005016859-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-02-24 — — WO disclosed
US-20040171556-A1 Methods for inhibiting proteasome BRISTOL-MYERS SQUIBB COMPANY 2004-09-02 — — US disclosed
WO-2003070971-A2 MODULATORS OF PARAPTOSIS AND RELATED METHODS BUCK INSTITUTE (US) 2003-08-28 — — WO disclosed
EP-1088100-A2 PROTEASOMAL ACTIVITY Zarpex Biosciences Limited (GB) 2001-04-04 — — EP disclosed
EP-1045860-A2 METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING INSULIN RELATED DISORDERS Duckworth, William Clifford (US) 2000-10-25 — — EP disclosed
WO-1999066065-A2 PROTEASOMAL ACTIVITY ZARPEX BIOSCIENCES LIMITED (GB) 1999-12-23 — — WO disclosed
WO-1999035169-A9 METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING INSULIN RELATED DISORDERS DUCKWORTH WILLIAM CLIFFORD (US) 1999-11-11 — — WO disclosed
WO-1999035169-A2 METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING INSULIN RELATED DISORDERS DUCKWORTH WILLIAM CLIFFORD (US) 1999-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 TDP1 1150/4885CA12 2578/4885CA1 902/4885
US-20040171556-A1 Methods for inhibiting proteasome PSMB1, PSMB11, PSMG3 TDP1 1835/4885CA12 4336/4885CA1 2793/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 TDP1 1150/4885CA12 2578/4885CA1 902/4885
US-20050059636-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 TDP1 1150/4885CA12 2578/4885CA1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.